Related Experiment Video
Updated: May 29, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in
Kang-Yu Lin1, Xing-Ju Zhang1, Dan-Dan Feng1
1Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory for Biocontrol, Sun Yat-sen University, Guangzhou 510275, China.
Abstract:
MicroRNA-125b (miR-125b), a small noncoding RNA molecule, has been found to be deregulated and functions as an oncogene in many cancers including hematopoietic malignancies. However, the mechanisms accounting for miR-125b dysregulation remain to be elucidated. The present study aims to identify the factors that might contribute to up-regulation of miR-125b in human hematopoietic malignancies and its downstream targets for lineage-specific differentiation. We at first reported that CDX2, a homeobox transcription factor, binds to promoter regions of the miR-125b gene and activates transcriptional regulation of miR-125b in malignant myeloid cells. We further revealed that increasing levels of CDX2 in malignant myeloid cells activate miR-125b expression, which in turn inhibits core binding factor β (CBFβ) translation, thereby counteracting myeloid cell differentiation, at least for granulocytic lineage, and promoting leukemogenesis. Interestingly, we found that this novel pathway including CDX2, miR-125b, and CBFβ was mediated by undergoing all-trans-retinoic acid induction. Once differentiation ensues with all-trans-retinoic acid treatment, CDX2 activity decreases, leading to a reduction in miR-125b transcription and up-regulation of CBFβ in myeloid cells and in patients. The study provides a new mechanism that contributes to hematopoietic malignancies, which could involve deregulation of miR-125b and its up- and downstream factors. As altered expression of miRNAs has been reported in a wide range of malignancies, delineating the underlying molecular mechanisms of aberrant miRNA expression and characterizing the upstream and downstream factors will help to understand important steps in the pathogenesis of these afflictions.
Insights
A new study reveals that the transcription factor CDX2 up-regulates microRNA-125b (miR-125b) in myeloid cells. This process inhibits core binding factor β (CBFβ) translation, promoting leukemogenesis and hindering myeloid cell differentiation.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- MicroRNA-125b (miR-125b) is deregulated and acts as an oncogene in various cancers, including hematopoietic malignancies.
- The precise mechanisms driving miR-125b dysregulation in these cancers are not fully understood.
- Identifying these mechanisms is crucial for understanding leukemogenesis and developing targeted therapies.
Purpose of the Study:
- To identify factors contributing to miR-125b up-regulation in human hematopoietic malignancies.
- To investigate the downstream targets of miR-125b involved in lineage-specific differentiation.
- To elucidate the role of CDX2, miR-125b, and CBFβ in myeloid cell differentiation and leukemogenesis.
Main Methods:
- Investigated the binding of transcription factor CDX2 to the miR-125b gene promoter.
- Analyzed the effect of CDX2 levels on miR-125b expression in malignant myeloid cells.
- Examined the impact of miR-125b on core binding factor β (CBFβ) translation.
- Studied the role of all-trans-retinoic acid (ATRA) in modulating the CDX2-miR-125b-CBFβ pathway.
Main Results:
- CDX2 directly binds to and activates the transcription of miR-125b in malignant myeloid cells.
- Elevated CDX2 levels lead to increased miR-125b expression, which suppresses CBFβ translation.
- This pathway inhibits myeloid cell differentiation, particularly granulocytic lineage, and promotes leukemogenesis.
- All-trans-retinoic acid treatment reduces CDX2 activity, decreasing miR-125b transcription and restoring CBFβ levels, thereby inducing differentiation.
Conclusions:
- A novel pathway involving CDX2, miR-125b, and CBFβ contributes to hematopoietic malignancies.
- Deregulation of miR-125b and its associated factors represents a key mechanism in leukemogenesis.
- Understanding this pathway provides new insights into the pathogenesis of hematopoietic malignancies and potential therapeutic targets.
More Related Videos
10:25Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
Published on: August 9, 2019
12:44Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis
Published on: November 11, 2014
Related Concept Videos
Master Transcription Regulators
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells
Lineage Commitment
Abnormal Proliferation
MicroRNAs